Athersys (NASDAQ:ATHX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research note published on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

The stock has a market capitalization of $833,000.00, a P/E ratio of -0.01 and a beta of -0.90. Athersys has a 52 week low of $0.01 and a 52 week high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.